Gilead Sciences Announces Leadership Changes in Corporate Development and Strategy
June 04 2018 - 5:00PM
Business Wire
– Andrew Dickinson Promoted to Executive
Vice President, Corporate Development and Strategy;Martin
Silverstein, Executive Vice President, Strategy, to Leave Gilead at
End of August –
Gilead Sciences, Inc. (NASDAQ: GILD) today announced the
promotion of Andrew Dickinson to Executive Vice President,
Corporate Development and Strategy, with responsibility for
Gilead’s corporate development, alliance management, competitive
intelligence, and corporate strategy and planning functions,
effective immediately. Mr. Dickinson will become a member of
Gilead’s senior leadership team. The company also announced that
Martin Silverstein, Executive Vice President, Strategy, has decided
to leave Gilead at the end of August to return to the East
Coast.
Mr. Dickinson joined Gilead in 2016 as Senior Vice President,
Corporate Development. He led the acquisitions of Kite Pharma, Inc.
and Cell Design Labs, Inc., and has been instrumental in reshaping
Gilead’s approach to corporate development, increasing the volume
and types of agreements that the company has entered into during
his tenure. Prior to joining Gilead, Mr. Dickinson served as Global
Co-Head of Healthcare Investment Banking for Lazard. At Lazard, he
advised on numerous, industry-defining merger and acquisition
transactions, as well as many other strategic matters across the
biopharmaceutical industry. Mr. Dickinson received his bachelor’s
degree in molecular, cellular and developmental biology from the
University of Colorado and his law degree from Loyola University
Chicago.
“Andy has brought to Gilead vision, creativity and leadership,
fundamentally changing the way that we assess and execute
acquisitions and partnerships as an organization,” said John F.
Milligan, PhD, President and Chief Executive Officer of Gilead.
“His deep understanding of the industry has helped guide Gilead’s
strategy and will be critical to our future success.”
Dr. Silverstein will remain at Gilead through the end of August,
working with Mr. Dickinson and other leaders to transition his
duties.
“I’m grateful to Marty for his exceptional work to strengthen
Gilead’s strategic planning and vision, and ensure that we are
well-positioned for future growth, as we seek to bring the next
generation of medicines forward for patients with unmet medical
needs,” said Dr. Milligan. “We understand his decision to eliminate
the bicoastal schedule he has kept since joining Gilead and be
closer to his family, and wish him the very best in the next phase
of his career.”
About Gilead Sciences
Gilead Sciences, Inc. is a research-based biopharmaceutical
company that discovers, develops and commercializes innovative
medicines in areas of unmet medical need. The company strives to
transform and simplify care for people with life-threatening
illnesses around the world. Gilead has operations in more than 35
countries worldwide, with headquarters in Foster City,
California.
Forward-Looking
Statement
This press release includes forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of 1995
that are subject to risks, uncertainties, and other factors. These
risks, uncertainties and other factors could cause actual results
to differ materially from those referred to in the forward-looking
statements. The reader is cautioned not to rely on these
forward-looking statements. These and other risks are described in
detail in Gilead’s Quarterly Report on Form 10-Q for the quarter
ended March 31, 2018, as filed with the U.S. Securities and
Exchange Commission. All forward-looking statements are based on
information currently available to Gilead, and Gilead assumes no
obligation to update any such forward-looking statements.
For more information on Gilead Sciences,
please visit the company’s website at www.gilead.com, follow
Gilead on Twitter (@GileadSciences) or call Gilead Public Affairs
at 1-800-GILEAD-5 or 1-650-574-3000.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20180604006286/en/
Gilead Sciences, Inc.InvestorsSung Lee, 650-524-7792orMediaAmy
Flood, 650-522-5643
Gilead Sciences (NASDAQ:GILD)
Historical Stock Chart
From Mar 2024 to Apr 2024
Gilead Sciences (NASDAQ:GILD)
Historical Stock Chart
From Apr 2023 to Apr 2024